Avant Technologies and Partner, Ainnova, Launch Transformative Preventative Care Model for Chronic Patients Across Latin America

Rhea-AI Summary

Avant Technologies (OTCQB: AVAI) and its joint venture partner Ainnova Tech have launched an innovative preventive care model in Latin America, focusing on diabetic patients. The model provides free retinal risk screenings at local pharmacies, shifting care from hospitals to convenient locations.

The initiative integrates key healthcare stakeholders including pharmacy chains, health clinics, insurance companies, and pharmaceutical partners. Ainnova's AI platform identifies at-risk patients before symptoms appear, enabling early intervention and better clinical outcomes.

Through Ai-Nova Acquisition Corp. (AAC), the companies hold worldwide licensing rights for Ainnova's technology portfolio. The company projects significant revenue growth for 2025 and 2026 as commercial agreements and pilot programs expand across multiple countries.

Positive

• Strategic partnership providing worldwide licensing rights for Ainnova's AI technology portfolio
• Projected explosive revenue growth for 2025 and 2026
• Commercial agreements and pilot programs already established in multiple countries
• Cost-free preventive care model eliminating barriers to early diagnosis
• Integration of multiple healthcare stakeholders creating a sustainable business model

Negative

• Operating in emerging markets which may present regulatory and implementation challenges
• Early stage of commercial deployment with unproven revenue projections
• Dependency on multiple stakeholders for successful implementation

LAS VEGAS, July 8, 2025 /PRNewswire/ -- Avant Technologies, Inc. (OTCQB: AVAI) ("Avant" or the "Company"), and its JV partner, Ainnova Tech, Inc., (Ainnova), a cutting-edge healthtech company leveraging artificial intelligence (AI) for early disease detection, today announced the launch of a new preventive care model that is reshaping how—and where—chronic patients receive care in Latin America.

At the heart of this model is a seamless experience for diabetic patients, who can now receive free retinal risk screenings at their neighborhood pharmacies, which will eliminate the barriers to an early diagnosis. This approach moves care out of the hospital and into every day, high-traffic locations—bringing timely early disease detection to the patient at a point of convenience.

Avant's partner, Ainnova, is spearheading this model across Latin America by successfully aligning key players in the healthcare ecosystem on a single, patient-centered mission, including pharmacy chains, health clinics, insurance companies, and pharmaceutical partners. All four groups are being integrated into this model, while a growing network of medical specialists receives timely referrals of patients identified as "at risk" through Ainnova's AI platform. It's an approach that enables earlier treatment, better clinical outcomes, and a more efficient use of healthcare resources.

This breakthrough is addressing one of the biggest challenges in chronic care: many patients, especially those with diabetes, lack awareness of the risks associated with their condition and do not seek specialist care until complications are advanced. Ainnova's solution is changing the industry—identifying risk before symptoms appear, and doing so in a way that is frictionless for the patient.  By activating those with the strongest incentive to intervene early, Ainnova has found a sustainable, scalable formula for delivering high-value preventive care—at no cost to the patient—and unlocking powerful new lines of collaboration across the industry.

With commercial agreements and pilot programs underway in several countries, the company is forecasting explosive revenue growth and a greater reach in both 2025 and 2026.

The launch of this preventive care model and the growth of Ainnova's revenue and reach is significant to Avant because the two companies formed Ai-Nova Acquisition Corp. (AAC) to develop and market Ainnova's technology portfolio, which includes its AI platform. AAC has the worldwide licensing rights for Ainnova's technology portfolio. The licensing rights include Latin America where this preventative model is being launched.

About Ainnova Tech, Inc.

Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce Vision AI – our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.

About Avant Technologies, Inc. 

Avant Technologies Inc. is an emerging technology company developing solutions in healthcare using artificial intelligence and biotechnologies. With a focus on pushing the boundaries of what is possible in AI and biotechnology, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.

More information about Avant can be found at https://avanttechnologies.com 

You can also follow us on social media at:

https://twitter.com/AvantTechAI https://www.linkedin.com/company/avant-technologies-ai 
https://www.facebook.com/AvantTechAI 
https://www.youtube.com/@AvantTechAI 

Forward-Looking Statements

Certain statements contained in this press release may constitute "forward-looking statements."  Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.  Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov).  In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products.  The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change.  However, while the Company may elect to update these forward-looking statements at some point in the future, the

Company specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.

Contact:
Avant Technologies, Inc. info@avanttechnologies.com

Logo: https://mma.prnewswire.com/media/2370694/5404726/Avant_Technologies.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avant-technologies-and-partner-ainnova-launch-transformative-preventative-care-model-for-chronic-patients-across-latin-america-302500064.html

SOURCE Avant Technologies Inc.

FAQ

What is the partnership between Avant Technologies (AVAI) and Ainnova Tech?

The companies formed Ai-Nova Acquisition Corp. (AAC) to develop and market Ainnova's technology portfolio, including its AI platform, with worldwide licensing rights.

How does AVAI's new preventive care model work in Latin America?

The model provides free retinal risk screenings for diabetic patients at local pharmacies, using AI technology to identify risks before symptoms appear and connecting at-risk patients with specialists.

What is the revenue outlook for Avant Technologies' (AVAI) new healthcare initiative?

The company forecasts explosive revenue growth for both 2025 and 2026, supported by commercial agreements and pilot programs in several countries.

Who are the key stakeholders in AVAI's Latin American healthcare model?

The model integrates pharmacy chains, health clinics, insurance companies, pharmaceutical partners, and medical specialists into a unified patient-centered system.

What problem does Avant Technologies' (AVAI) new healthcare model solve?

It addresses the challenge of diabetic patients lacking awareness of health risks by providing convenient, free early detection services at neighborhood pharmacies instead of hospitals.